LKT Laboratories, Inc.

Belinostat

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B1746
CAS No. 414864-00-9
Chemical Name

Synonym PXD101



Formula $C_{15}H_{14}N_2O_4S$
Formula Wt. 318.35
Melting Point
Purity ≥98%
Solubility

DMSO	64 mg/mL (201.03 mM)
Water	Insoluble
Ethanol	Insoluble

Bulk quanitites available upon request

Product ID	Size
B1746	5 mg
B1746	10 mg

Store Temp -20°C
Ship Temp Ambient

Description Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.

References

Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print]. PMID: 25404094.

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.